The impact of clotting factor concentrates on the immune system in individuals with hemophilia.
All reported studies to date, whether comparative or not, have shown a tendency toward a slower decrease in CD4+ numbers in patients receiving very high-purity agents with the rapidity in fall-off being affected by level of CD4+ numbers (low CD4+ numbers decreasing more rapidly), age (older persons showing more rapid CD4+ cell fall-off), and anti-HIV therapy. Clearly, these observations need to be extended in numbers, and the high-purity agents should also be similarly compared with the very high-purity therapies.
Baxter Healthcare Corporation, Hyland Division, Glendale, CA 91203.
E D
ED
Gomperts
R
R
de Biasi
R
R
De Vreker
D000941:Antigens / Q000276:immunology; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D001798:Blood Proteins / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004340:Drug Contamination; D015658:HIV Infections / Q000276:immunology / Q000635:transmission; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D014777:Virus Diseases / Q000276:immunology / Q000635:transmission
D000941:Antigens; D001779:Blood Coagulation Factors; D001798:Blood Proteins